An agreement could be announced as soon as Tuesday and would value Masimo, a maker of patient monitoring systems, at a premium to its almost $7 billion market capitalization at Friday’s close, the newspaper said. Neither Danaher nor Masimo immediately responded to the FT’s requests for comment.
The purchase would mark Danaher’s largest acquisition since its more than $21 billion takeover in 2020 of Cytiva, the biologics manufacturing unit ...